AMRN
USDAmarin Corporation plc
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$15.670
Haut
$15.745
Bas
$15.110
Volume
0.06M
Fondamentaux de l'Entreprise
Capitalisation Boursière
326.7M
Industrie
Drug Manufacturers - General
Pays
Ireland
Statistiques de Trading
Volume Moyen
0.10M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Rapport d'Analyse IA
Dernière mise à jour: 5 nov. 2025AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares
Key Takeaways
- Recent technical indicators show bullish momentum but conflicting signals
- Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
- Stock trades at historical discount to 52-week highs but risks remain
- Fundamental risks outweigh short-term value opportunities
Recent News Impact
Positive Developments
- Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
- FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.
Mixed Earnings Release (Oct 29, 2025)
Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.
Actualités Connexes
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
Prédiction IABeta
Recommandation IA
Mis à jour le: 10 nov. 2025, 13:07
58.4% Confiance
Risque et Trading
Point d'Entrée
$15.36
Prise de Bénéfices
$15.93
Stop Loss
$14.06
Facteurs Clés
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.